基石药业-B2023年中期报告

Interim Report中期報告2023 2 4 5 13 27 37 55 56 57 59 60 61 79 Paul Herbert Chew Kenneth Walton Hitchner III Kenneth Walton Hitchner III Paul Herbert Chew Paul Herbert Chew www.cstonepharma.com Paul Herbert Chew Vistra (Cayman) LimitedP.O. Box 31119, Grand PavilionHibiscus Way802 West Bay RoadGrand Cayman KY1-1205Cayman Islands Paul Herbert Chew 2125B 218C1 24840 2616 •8835 Walkers Corporate LimitedCayman Corporate Centre27 Hospital RoadGeorge TownGrand Cayman KY1-9008Cayman Islands 183171712-1716 826 •261.5246.914.6161.485.553%13.11.511% •266.679.8186.8 •134.845.689.2 •146.415.0131.4 •361.6152.442%209.2 •218.920.8198.1 •224.441.3183.1•257.174.129%183.0 261.5246.914.6 N D AR E TN S C L CN S C L CR E TNSCLCRETMTCRETTC NDAR/RTENKTLIVNSCLCIVNSCLCGC/GEJESCCEMAIVNSCLCGCP CS5001CS50011ROR1ADCFIH c-rosoncogene 1ROS1NSCLCnofazinlimabLENVIMA®(lenvatinib)HCCIII ESMOESMO GINature Cancer CPTCPTPoC CDE I. • ®®®246.9 • ®RETNSCLC®RETNSCLCRETMTCRETTC • 80018085075%80% • RETNSCLC/TCG I S TαP D G F R A181IDH1AMLLCPANSCLCRET PQCC RETNSCLC/MTCIDH1AML1,200 • ®®®21NSCLCTCGISTSMAML(CSCO)2023CSCO20222022CACA2022 C S C OC A C AGISTNSCLCMTC IITRWSRWS®GISTIIT®KIT D816N822R/R AML • ®PAP®PAPGIST®PAPDOT ®®®1381 ®®®®®®300DTP220 •DOT DOT8,00033020020,000 • IIINSCLCCSCO2023CSCO20231IV2023 II. •CS1001PD-L1 IVNSCLC •IVNSCLCMAANSCLCMAAEMAMHRAEMAGCP•IVNSCLCGEMSTONE-302OSNature Cancer GC/GEJ •GC/GEJNDA•GC/GEJOS ESCC •ESCCNDA•E S C CGEMSTONE-304PFSOSESMO GI R/R ENKTL •R/R ENKTLGEMSTONE-201 •CS3009RET TFDARETNSCLCRETMTCRETTCNDARETNSCLCNDARETNSCLCI/IIARROWCancer •CS5001(LCB71 ROR1 ADC) BICROR1ADCFIHROR1ADCCS5001 C S5001ROR1ADCCS5001BICCS5001ROR113ADCADCCS5001 ROR1ROR1IHC •CS3010IDH1 R/R AMLCDER/RAML •CS3007KIT/PDGFRA B l u e p r i n tM e d i c i n e s C o r p o r a t i o nB l u e p r i n tMedicinesFDANDA ASCOGIST •ALK/ROS-1 ROS1NSCLC III. ADC •FICADCsADCPCCIND •CS2009PD-1VEGFINDINDPCC • IV. BlueprintMedicinesBlueprintMedicinesBlueprintMedicines CTLA-4(CS1002)CS1002HCCNSCLCIb/II EQRxnofazinlimabnofazinlimabEMAMHRAMAAEQRxnofazinlimab V. CDE ••••DTP•• NDA •R/R ENKTLNDA•IVNSCLCMAA•IVNSCLCMAA•GC/GEJNDA•ESCCNDA NDA •ROS1NSCLCNDA •NofazinlimabnofazinlimabLENVIMA® (lenvatinib)HCCIII •CS5001 14NDA 18085075%80%®®®246.9 •® ®RETRETNSCLC1RETNSCLC2RETMTCRETTC®RETNSCLCTFDARETNSCLCRETMTCRETTC ®®CSCO2023RET®RETNSCLC CSCO2023NSCLCTCRET200RET80% NSCLC RET® ®®138200DTP®PAP •® ®KIT/PDGFRAPDGFRA18PDGFRAD842VGIST®TFDAPDGFRA D842VGIST®®CSCO20222022PDGFRA18GISTPDGFRA18GIST10080%CSCOGISTGIST®®GIST®®10880DTPPAPGIST •® ®IDH1IDH1R/RAMLIDH1AMLAMLIDH1KinstarGlobalIDH1IDH120080%®®9780DTP®PAPDOT • IIINSCLCCSCO2023CSCO2023IIV2023 CS3009RET •TFDARETNSCLCRETMTCRETTCNDA•RETNSCLCNDA•CancerRETNSCLCI/IIARROWRETNSCLC CS3007KIT/PDGFRA •ASCOGISTKITATPKIT •BlueprintMedicinesFDANDA CS3010IDH1 •R/R AML •CDER/RAML CS1001PD-L1 •PD-L1IIIIVNSCLCPD-L1GIgG4IIIVNSCLCIIINSCLCIII •IVNSCLC IVNSCLCMAANSCLCMAAEMAMHRAEMA IVNSCLCGEMSTONE-302OSNature Cancer •GC/GEJ GC/GEJNDAGC/GEJOS •ESCC ESCCNDA ESCCGEMSTONE-304PFSOSESMO GI •R/R ENKTL R/RENKTLGEMSTONE-201 18A.05 CS5001 (LCB71ROR1 ADC) •ROR1ADCFIHROR1ADCCS5001 •C S 5 0 0 1ROR1ADCCS5001BICCS5001ROR113ADCCS5001 •ROR1ROR1 ALK/ROS-1 •ROS1NSCLCINDROS1NSCLC ADC ADCADCIND CS2009PD-1VEGFINDINDPCC • IVNSCLCIIINSCLCIIINSCLCPFSPD-1/PD-L1 ROS1NSCLCROS1NSCLC •Blueprint Medicines BlueprintMedicinesBlueprintMedicinesBlueprint Medicines • CTLA-4(CS1002)2CS1002CS1002CS1002Ib/IIINDHCCNSCLC •EQRx EQRxnofazinlimabnofazinlimabEMAMHRAMAAEQRxnofazinlimab • COVID-19 COVID-19 261.5246.914.6161.485.553%13.11.511% 5.820.025.8 14.310.524.827.3 266.679.8186.8(i)127.781.246.5(ii)137.315.3122.0(iii)16.6 134.845.689.295.133.461.7 146.415.0131.4 2.93.05.9 1994932194 12.00186,396,0000.0001146,294.762,090.16H.10 13.37115,928,803200.01,355.9 4.63384,800,0005.080.00018,480389.07338.124.59 1,005.41,042.1 1 0 0 %63.6%72.6% 1752510050100,000,000154,283,000 M.D.,Ph.D.59 25BGNE6160688235PD-1BTKPARP CovanceInc.Tularik Inc.Amgen Inc. 50 MichaelS.BrownJosephL.GoldsteinStuartL.Schreiber Ph.D.51 20CreacionVentures6Dimensions Capital,L.P.WuXiHealthcareVenturesII,L.P.1477 MBA KennethWalton Hitchner III63Hitchner Hitchner30 HitchnerProvidentAcquisition Corp.PAQCValianceAssetManagementHitchner Hitchner2269HitchnerElementsAdvisors SPVAntler6032592359HitchnerHH&LAcquisitionCo.HHLAHitchnerCydar MedicalSphere Fluidics Hitchner 53 2157 60 1228 •AmbrxBiopharma Inc.AMAM•2269 •Viela Bio Inc.VIE•WuXiPharmaTech(Cayman)Inc.•TanoxInc.TNOXGenentech Inc.•BiogenInc.BIIB• (Carnegie Mellon University) PaulHerbert ChewM.D.71Chew ChewPhesiChewCorMedix,IncChewArisGlobalFDA140 ChewChewOmadaHealthChewChew GBS,JP69 870011406110515150006096625001477 SincereWatch(Hong Kong)Limited044412880270 (Teesside Polytechnic) •••• 47 2015181860225608532252 M.D.,Ph.D.59 M.D.,Ph.D.56 21CTLA4STINGNanobodiesDaiichi Sankyo Pharma DevelopmentDa